Steroid cataracts in children

Article

Paediatric subjects who require frequent steroid therapy are at an increased risk of developing amblyopia due to cataracts, according to a study published online ahead of print by Pediatrics International, the official English language publication of the Japan Pediatric Society.

Paediatric subjects who require frequent steroid therapy are at an increased risk of developing amblyopia due to cataracts, according to a study published online ahead of print by Pediatrics International, the official English language publication of the Japan Pediatric Society.

Yasuhito Nerome, MD of the Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan and colleagues evaluated risk factors for the formation of cataracts in paediatric subjects.

The researchers found a positive association between cataract formation and intravenous methylprednisone pulse (IVMP) therapy in subjects aged ≤12 years. No relationship to cataract formation was found to exist with either the doses (cumulative or daily) of steroids used or with patient gender.

Thus the researchers recommended that, since corticosteroid use is associated with cataract formation in paediatric subjects, these patients be examined by ophthalmologists frequently, to reduce the risk of amblyopia.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.